• 1
    Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009;13:21930.
  • 2
    Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 2006;13:17587.
  • 3
    Yassen A, Olofsen E, Dahan A, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 2005;313:113649.
  • 4
    Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005;29:297326.
  • 5
    Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol 2009;5:23041.
  • 6
    Suri A, Estes KS, Geisslinger G, Derendorf H. Pharmacokinetic-pharmacodynamic relationships for analgesics. Int J Clin Pharmacol Ther 1997;35:30723.
  • 7
    Drewes AM, Schipper KP, Dimcevski G, Petersen P, Andersen OK, Gregersen H et al. Multi-modal induction and assessment of allodynia and hyperalgesia in the human oesophagus. Eur J Pain 2003;7:53949.
  • 8
    Staahl C, Drewes AM. Experimental human pain models: a review of standardised methods for preclinical testing of analgesics. Basic Clin Pharmacol Toxicol 2004;95:97111.
  • 9
    Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005;5(Suppl):S90103.
  • 10
    Sittl R, Nuijten M, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther 2005;27:102231.
  • 11
    Hamilton RC, Dundee JW, Clarke RS, Loan WB, Morrison JD. Alterations in response to somatic pain associated with anaesthesia. 18. Studies with some opiate antagonists. Br J Anaesth 1967;39:490502.
  • 12
    Curatolo M, Petersen-Felix S, rendt-Nielsen L. Sensory assessment of regional analgesia in humans: a review of methods and applications. Anesthesiology 2000;93:151730.
  • 13
    Svensson P, Cairns BE, Wang K, Arendt-Nielsen L. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. Pain 2003;2: 2417.
  • 14
    Torebjork HE, Lundberg LE, LaMotte RH. Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia in humans. J Physiol 1992;448:76580.
  • 15
    NONMEM User′s Guides [computer program]. 2006.
  • 16
    Kass R, Raftery A. Bayes factors. J Am Stat 1995;90:77395.
  • 17
    Olesen AE, Upton R, Foster D, Staahl C, Christrup L, Arendt-Nielsen L. et al. Pharmacokinetic and Pharmacodynamic Study of Oral Oxycodone in a Human Experimental Pain Model of Hyperalgesia. Clin Pharmacokinet 2010;49:81727.
  • 18
    Hull CJ, Van Beem HB, McLeod K, Sibbald A, Watson MJ. A pharmacodynamic model for pancuronium. Br J Anaesth 1978;50:111323.
  • 19
    Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979;25: 35871.
  • 20
    Staahl C, Olesen AE, Andresen T, Arendt-Nielsen L, Drewes AM. Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review. Br J Clin Pharmacol 2009;68:14968.
  • 21
    Koltzenburg M, Pokorny R, Gasser UE, Richarz U. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain 2006;3:16574.
  • 22
    Cavero I. Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society. Expert Opin Drug Saf 2007;6:46571.
  • 23
    Gourlay GK, Kowalski SR, Plummer JL, Cousins MJ, Armstrong PJ. Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg 1988;67:32937.
  • 24
    Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 1997;35:40113.
  • 25
    Yassen A, Olofsen E, Romberg R, Sarton E, Danhof M, Dahan A. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 2006;104:123242.
  • 26
    Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:62732.
  • 27
    Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003;2(Suppl):S1327.
  • 28
    Jensen ML, Sjogren P, Upton RN, Foster DJ, Bonde P, Graae C et al. Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers. Basic Clin Pharmacol Toxicol 2008;103:94101.
  • 29
    Bouhassira D, Chitour D, Villanueva L, Le BD. Morphine and diffuse noxious inhibitory controls in the rat: effects of lesions of the rostral ventromedial medulla. Eur J Pharmacol 1993;3:20715.
  • 30
    Le BD, Chitour D, Kraus E, Clot AM, Dickenson AH, Besson JM. The effect of systemic morphine upon diffuse noxious inhibitory controls (DNIC) in the rat: evidence for a lifting of certain descending inhibitory controls of dorsal horn convergent neurones. Brain Res 1981;2:25774.
  • 31
    Willer JC, Le BD, De BT. Diffuse noxious inhibitory controls in man: involvement of an opioidergic link. Eur J Pharmacol 1990;2:34755.
  • 32
    Arendt-Nielsen L, Curatolo M, Drewes A. Human experimental pain models in drug development: translational pain research. Curr Opin Investig Drugs 2007;8:4153.
  • 33
    Negus SS, Vanderah TW, Brandt MR, Bilsky EJ, Becerra L, Borsook D. Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. J Pharmacol Exp Ther 2006;319:50714.
  • 34
    Liu M, Max MB, Robinovitz E, Gracely RH, Bennett GJ. The human capsaicin model of allodynia and hyperalgesia: sources of variability and methods for reduction. J Pain Symptom Manage 1998;16:1020.
  • 35
    Scanlon GC, Wallace MS, Ispirescu JS, Schulteis G. Intradermal capsaicin causes dose-dependent pain, allodynia, and hyperalgesia in humans. J Investig Med 2006;54:23844.
  • 36
    Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001;297:68895.
  • 37
    Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995;272:50510.
  • 38
    Pontani RB, Vadlamani NL, Misra AL. Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica 1985;15:28797.
  • 39
    Yue H, Borenstein MR, Jansen SA, Raffa RB. Liquid chromatography-mass spectrometric analysis of buprenorphine and its N-dealkylated metabolite norbuprenorphine in rat brain tissue and plasma. J Pharmacol Toxicol Methods 2005;52:31422.
  • 40
    Jensen ML, Foster D, Upton R, Grant C, Martinez A, Somogyi A. Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. Xenobiotica 2007;37:44157.